Abstract

PTPN2 (protein tyrosine phosphatase non-receptor type 2, or TC-PTP) and PTPN1 are attractive immuno-oncology targets, with the deletion of Ptpn1 and Ptpn2 improving response to immunotherapy in disease models. Targeted protein degradation has emerged as a promising approach to drug challenging targets including phosphatases. We developed potent PTPN2/N1 dual heterobifunctional degraders (Cmpd-1 and Cmpd-2) which facilitate efficient complex assembly with E3 ubiquitin ligase CRL4CRBN, and mediate potent PTPN2/N1 degradation in cells and mice. To provide mechanistic insights into the cooperative complex formation introduced by degraders, we employed a combination of structural approaches. Our crystal structure reveals how PTPN2 is recognized by the tri-substituted thiophene moiety of the degrader. We further determined a high-resolution structure of DDB1-CRBN/Cmpd-1/PTPN2 using single-particle cryo-electron microscopy (cryo-EM). This structure reveals that the degrader induces proximity between CRBN and PTPN2, albeit the large conformational heterogeneity of this ternary complex. The molecular dynamic (MD)-simulations constructed based on the cryo-EM structure exhibited a large rigid body movement of PTPN2 and illustrated the dynamic interactions between PTPN2 and CRBN. Together, our study demonstrates the development of PTPN2/N1 heterobifunctional degraders with potential applications in cancer immunotherapy. Furthermore, the developed structural workflow could help to understand the dynamic nature of degrader-induced cooperative ternary complexes.

PTPN2 (protein tyrosine phosphatase non-receptor type 2) and PTPN1 are attractive immuno-oncology targets, however, targeting PTPN2/N1 poses significant challenges. Here, the authors report the development of potent PTPN2/N1 heterobifunctional degraders and reveal biochemical and structural insights into the formation of ternary structures with cereblon E3 ligase by X-ray diffraction, cryo-EM and MD simulations.

Details

Title
Mechanistic insights into a heterobifunctional degrader-induced PTPN2/N1 complex
Author
Hao, Qi 1   VIAFID ORCID Logo  ; Rathinaswamy, Manoj K. 1 ; Klinge, Kelly L. 2 ; Bratkowski, Matthew 1   VIAFID ORCID Logo  ; Mafi, Amirhossein 1 ; Baumgartner, Christina K. 2 ; Hamel, Keith M. 2 ; Veits, Gesine K. 3 ; Jain, Rinku 2 ; Catalano, Claudio 4   VIAFID ORCID Logo  ; Fitzgerald, Mark 3 ; Hird, Alexander W. 3 ; Park, Eunice 3 ; Vora, Harit U. 3 ; Henderson, James A. 3 ; Longenecker, Kenton 2 ; Hutchins, Charles W. 2 ; Qiu, Wei 2 ; Scapin, Giovanna 4 ; Sun, Qi 2 ; Stoll, Vincent S. 2 ; Sun, Chaohong 2 ; Li, Ping 3 ; Eaton, Dan 1   VIAFID ORCID Logo  ; Stokoe, David 1 ; Fisher, Stewart L. 3 ; Nasveschuk, Christopher G. 3   VIAFID ORCID Logo  ; Paddock, Marcia 1 ; Kort, Michael E. 2 

 Calico Life Sciences LLC, South San Francisco, USA (GRID:grid.497059.6) 
 1 North Waukegan Rd, AbbVie, North Chicago, USA (GRID:grid.431072.3) (ISNI:0000 0004 0572 4227) 
 490 Arsenal Way, C4 Therapeutics Inc., Watertown, USA (GRID:grid.504874.a) 
 4-C Gill Street, Nanoimaging, Woburn, USA (GRID:grid.431072.3) 
Pages
183
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23993669
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3093692210
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.